Benjamin Djulbegovic, MD, PhD

Dr. Djulbegovic is a Distinguished Professor and Professor of Medicine and Oncology at the University of South Florida and Moffitt Cancer Center. His major academic research interests lie in the areas of evidence-based medicine, decision-analysis, clinical reasoning, systematic reviews/meta-analysis and comparative effectiveness research, ethics of clinical trials, practice guidelines, outcomes research, the impact of clinical trials and the role of uncertainty in medicine.  To date, Dr. Djulbegovic has published more than 190 papers in peer-review journals on these topics. 

• Miladinovic B, Mhaskar R, Hozo I, Kumar A, Mahony H, Djulbegovic B. Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. J Clin Epidemiol. 2013 Jun;66(6):654-659. Pubmedid: 23403248.
• El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 2013 May;5(5):457-466. Pubmedid: 23638742.
• Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol. 2013 May. Pubmedid: 23664493.
• Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar;368(12):1131-1139. Pubmedid: 23514290.
• Miladinovic B, Kumar A, Hozo I, Mahony H, Djulbegovic B. Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials. Contemp Clin Trials. 2013 Mar;34(2):257-261. Pubmedid: 23274403.
• Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, Haddow JE, Klein RD, Lyman DO, Offit K, Pauker SG, Piper M, Richards CS, Strickland OL, Tunis SR, Veenstra DL. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genet Med. 2013 Feb. Pubmedid: 23429431.
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple Myeloma, Version 1.2013. J Natl Compr Canc Netw. 2013 Jan;11(1):11-17. Pubmedid: 23307977.
• Mann H, Djulbegovic B. Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med. 2013 Jan;106(1):30-33. Pubmedid: 23358277.
• Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med. 2013 Jan;15(1):14-24. Pubmedid: 22955111.
• Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2:10. Pubmedid: 23379753. Pmcid: PMC3579762.
• Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One. 2013;8(3):e58711. Pubmedid: 23555593.
• Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013;6:2. Pubmedid: 23289975.
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. J Natl Compr Canc Netw. 2012 Oct;10(10):1211-1219. Pubmedid: 23054875.
• Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant. 2012 Sep;47(9):1164-1170. Pubmedid: 22562081.
• Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Towards a classification model to identify hospice candidates in terminally ill patients. Conf Proc IEEE Eng Med Biol Soc. 2012 Aug;2012:1278-1281. Pubmedid: 23366132.
• Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol. 2012 Jun;65(6):602-609. Pubmedid: 22424985. Pmcid: PMC3637913.
• Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis. Cancer Treat Rev. 2012 Jun. Pubmedid: 22703832.
• Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May;10(5):628-653. Pubmedid: 22570293.
• Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012 Apr;26(4):582-588. Pubmedid: 22182922.
• Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB. Ann Intern Med. 2012 Mar. Pubmedid: 22454395.
• Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB. Ann Intern Med. 2012 Mar;E-429. Pubmedid: 22711030.
• La Caze A, Djulbegovic B, Senn S. What does randomisation achieve?. Evid Based Med. 2012 Feb;17(1):1-2. Pubmedid: 21693455.
• Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Slingluff CL. Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012 Jan;18(1):256-262. Pubmedid: 21976533.
• Djulbegovic B, Hozo I. When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Med Res Methodol. 2012;12:85. Pubmedid: 22726276. Pmcid: PMC3473303.
• Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188. Pubmedid: 22592688.
• Djulbegovic B, Hozo I, Beckstead J, Tsalatsanis A, Pauker SG. Dual processing model of medical decision-making. BMC Med Inform Decis Mak. 2012;12:94. Pubmedid: 22943520. Pmcid: PMC3471048.
• Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I. New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev. 2012;10:MR000024. Pubmedid: 23076962. Pmcid: PMC3490226.
• Miladinovic B, Kumar A, Mhaskar R, Kim S, Schonwetter R, Djulbegovic B. A flexible alternative to the cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival. PLoS One. 2012;7(10):e47804. Pubmedid: 23082220.
• Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials. 2011 Oct;8(5):591-600. Pubmedid: 21878447. Pmcid: PMC3474201.
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct;9(10):1146-1183. Pubmedid: 21975914.
• Djulbegovic B. Uncertainty and equipoise: at interplay between epistemology, decision making and ethics. Am J Med Sci. 2011 Oct;342(4):282-289. Pubmedid: 21817885. Pmcid: PMC3183244.
• Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Rough Set Theory based prognostication of life expectancy for terminally ill patients. Conf Proc IEEE Eng Med Biol Soc. 2011 Aug;2011:6438-6441. Pubmedid: 22255812.
• Tsalatsanis A, Gil-Herrera E, Yalcin A, Djulbegovic B, Barnes L. Designing patient-centric applications for chronic disease management. Conf Proc IEEE Eng Med Biol Soc. 2011 Aug;2011:3146-3149. Pubmedid: 22255007.
• Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun;64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
• Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. JAMA. 2011 May;305(19):2005-2006. Pubmedid: 21586716.
• Djulbegovic M, Djulbegovic B. Implications of the principle of question propagation for comparative-effectiveness and "data mining" research. JAMA. 2011 Jan;305(3):298-299. Pubmedid: 21245185.
• Kumar A, Galeb S, Djulbegovic B. Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol. 2011 Jan;125(1-2):8-22. Pubmedid: 21150183.
• Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol. 2011 Jan;86(1):18-24. Pubmedid: 21120867.
• Dahm P, Djulbegovic B. The Australian 'FORM' approach to guideline development: the quest for the perfect system. BMC Med Res Methodol. 2011;11:17. Pubmedid: 21324126. Pmcid: PMC3055217.
• Tsalatsanis A, Barnes LE, Hozo I, Djulbegovic B. Extensions to Regret-based Decision Curve Analysis: An application to hospice referral for terminal patients. BMC Med Inform Decis Mak. 2011;11:77. Pubmedid: 22196308.
• Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011;(10):CD008818. Pubmedid: 21975786.
• Miladinovic B, Kumar A, Hozo I, Djulbegovic B. Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC Med Res Methodol. 2011;11:55. Pubmedid: 21510899.
• Tsalatsanis A, Barnes L, Hozo I, Skvoretz J, Djulbegovic B. A social network analysis of treatment discoveries in cancer. PLoS One. 2011;6(3):e18060. Pubmedid: 21464896. Pmcid: PMC3065482.
• Roback JD, Murad MH, Djulbegovic B. In reply. Transfusion. 2010 Dec;50(12):2763-2764. Pubmedid: 21126253.
• Mhaskar AR, Quinn G, Vadaparampil S, Djulbegovic B, Gwede CK, Kumar A. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials. Cancer Treat Rev. 2010 Dec;36(8):621-628. Pubmedid: 20444550.
• Wager E, Mhaskar R, Warburton S, Djulbegovic B. JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS One. 2010 Oct;5(10):e13591. Pubmedid: 21042585.
• Tsalatsanis A, Hozo I, Vickers A, Djulbegovic B. A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak. 2010 Sep;10:51. Pubmedid: 20846413.
• Schroen AT, Petroni GR, Hongkun Wang, Gray R, Wang XF, Cronin WM, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials. 2010 Aug;7(4):312-321. Pubmedid: 20595245.
• Herold CI, Djulbegovic B, Hozo I, Lyman GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Res Treat. 2010 Jun;121(3):771-776. Pubmedid: 19806449.
• Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010 Mar;303(12):1180-1187. Pubmedid: 20332404.
• Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010 Mar;(3):CD003188. Pubmedid: 20238320.
• Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-342. Pubmedid: 19850902. Pmcid: PMC2817042.
• Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543. Pubmedid: 20843937. Pmcid: PMC2939952.
• Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Nov;15(11):1415-1421. Pubmedid: 19822301.
• Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. Cancer Control. 2009 Oct;16(4):342-347. Pubmedid: 19910921. Pmcid: PMC2782889.
• Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct;7(9):908-942. Pubmedid: 19878637.
• Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-1013. Pubmedid: 19660713.
• Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. 2009 Aug;15(8):893-902. Pubmedid: 19589478.
• Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun;301(22):2349-2361. Pubmedid: 19509382. Pmcid: PMC3163846.
• Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009 Jun;27(18):3036-3043. Pubmedid: 19414675.
• Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun;15(11):3850-3855. Pubmedid: 19458059. Pmcid: PMC3296235.
• Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009 May;373(9674):1532-1542. Pubmedid: 19410717.
• Djulbegovic B, Guyatt GH, Ashcroft RE. Epistemologic inquiries in evidence-based medicine. Cancer Control. 2009 Apr;16(2):158-168. Pubmedid: 19337202.
• Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jan;101(2):100-106. Pubmedid: 19141779.
• Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;(3):CD007303. Pubmedid: 19588423.
• Djulbegovic B, Trikalinos TA, Roback J, Chen R, Guyatt G. Impact of quality of evidence on the strength of recommendations: an empirical study. BMC Health Serv Res. 2009;9:120-. Pubmedid: 19622148. Pmcid: PMC2722589.
• Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schünemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials. 2009;10:49-. Pubmedid: 19580665. Pmcid: PMC2723099.
• Hozo I, Djulbegovic B. When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach. Med Decis Making. 2008 Jul-Aug;28(4):540-553. Pubmedid: 18480041.
• Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul;45(3):150-159. Pubmedid: 18582621.
• Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet. 2008 May;371(9625):1642-1644. Pubmedid: 18486726.
• Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar;168(6):632-642. Pubmedid: 18362256. Pmcid: PMC2773511.
• Fletcher J, Djulbegovic B, Soares H, Siegel B, Lowe V, Lyman G, ColemanRE, Wahl R, Paschold J, Avril N, Einhorn L, Suh W, Samson D, Delbeke D, GormanM, Shields A. Recommendations on the Use of 18F-FDG PET in Oncology. J Nucl Med. 2008 Mar;49(3):458-508. Pubmedid: 18287273.
• Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb;299(8):914-924. Pubmedid: 18314434.
• Djulbegovic B. Evidence-Based Medicine: In Its Place. Med Decis Making. 2008 Feb; . Pubmedid: 18270305.
• Rizzo JP, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan;26(1):132-149. Pubmedid: 17954713.
• Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan;111(1):25-41. Pubmedid: 17954703.
• Wilcox R, Djulbegovic B, Moffitt H, Guyatt G, Montori V. Randomized trials in oncology stopped early for benefit. J Clin Oncol. 2008 Jan;26(1):18-9. Review. Pubmedid: 18165635.
• Djulbegovic B, Hozo I, Lyman G. Estimating net benefits and harms of screening mammography in women age 40 to 49 years. Ann Intern Med. 2007 Dec;147(12):882-882. Pubmedid: 18087062.
• Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.
• Kharfan-Dabaja M, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stemcell transplantation for chronic lymphocytic leukaemia: what is the publishedevidence. Br J Haematol. 2007 Oct;139(2):234-242. Pubmedid: 17897299.
• Djulbegovic B, Angelotta C, Knox K, Bennett C. The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol. 2007 Aug;25(24):3567-3569. Pubmedid: 17704401.
• Bennett C, Nebeker J, Yarnold P, Tigue C, Dorr D, McKoy J, Edwards B, Hurdle J, West D, Lau D, Angelotta C, Weitzman S, Belknap S, Djulbegovic B, Tallman M, Kuzel T, Benson A, Evens A, Trifilio S, Courtney D, Raisch D. Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med. 2007 May;167(10):1041-1049. Pubmedid: 17533207.
• Kumar A, Soares H, Balducci L, Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007 Apr;25(10):1272-1276. Pubmedid: 17401017.
• Behera M, Kumar A, Soares H, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007 Apr;14(2):160-166. Pubmedid: 17387301.
• Djulbegovic B. Articulating and responding to uncertainties in clinical research. J Med Philos. 2007 Mar;32(2):79-98. Pubmedid: 17454416.
• Koreth J, Cutler C, Djulbegovic B, Behl R, Schlossman R, Munshi N, Richardson P, Anderson K, Soiffer R, Alyea EP 3rd. High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Biol Blood Marrow Transplant. 2007 Feb;13(2):183-196. Pubmedid: 17241924.
• Djulbegovic B, Hozo I. When should potentially false research findings be considered acceptable. Plos Med. 2007 Feb;4(2):e26-e26. Pubmedid: 17326703.
• Anderson K, Alsina M, Bensinger W, Biermann J, Chanan-Khan A, Comenzo R, De Castro C, Djulbegovic B, Farag S, Huff C, Meredith R, Schriber J, ShrieveD, Singhal S, Smith M, Stockerl-Goldstein K, Vose J, Weber D, Yahalom J, YunusF. Multiple myeloma guidelines. J Natl Compr Canc Netw. 2007 Feb;5(2):118-147. Pubmedid: 17335683.
• Soares H, Kumar A, Djulbegovic B. Evidence profiles for breast cancer: Benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2007 Feb;33(1):87-89. Pubmedid: 17081695.
• Scheetz MH, McKoy JM, Parada J, Djulbegovic B, Raisch D, Yarnold PR, Zagory J, Trifilio S, Jakiche R, Palella F, Kahn A, Chandler K, Bennett CL. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30(4):295-306. Pubmedid: 17408306.
• Soares H, Kumar A, Djulbegovic B. Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev. 2006 Dec;32(8):652-655. Pubmedid: 17008011.
• Djulbegovic B, Lyman G. Screening mammography at 40-49 years: regret or no regret. Lancet. 2006 Dec;368(9552):2035-2037. Pubmedid: 17161713.
• Djulbegovic B, Soares H, Kumar A. What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. 2006 Nov;32(7):572-576. Pubmedid: 16914268.
• Kumar A, Soares H, Djulbegovic B. Evidence profiles for colo-rectal cancer: Benefit/harms data based on the totality of randomized evidence. 2006 Nov;32(7):577-580. Pubmedid: 16919883.
• Fisher R, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, Epner E, Krishnan A, Leonard J, Lonial S, Stadtmauer E, O'Connor O, Shi H, Boral A, Goy A. Multicenter phase II study of bortezomib in patients with relapsed orrefractory mantle cell lymphoma. J Clin Oncol. 2006 Oct;24(30):4867-4874. Pubmedid: 17001068.
• Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett C, Langensiepen S, Hyde C, Engert E. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006 Jul;3:CD003407-CD003407. Pubmedid: 16856007.
• Pavlidis N, Stahel R, Clarke M, Djulbegovic B. Cancer treatment reviews welcomes submission of the Cochrane Reviews. Cancer Treat Rev. 2006 Jun;32(4):243-244. Pubmedid: 16713102.
• Kumar A, Djulbegovic B. Multiple myeloma. Clin Evid. 2006 Jun;(15):1-29. Pubmedid: 16973003.
• Djulbegovic B. Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. J Eval Clin Pract. 2006 Jun;12(3):257-259. Pubmedid: 16722903.
• Glasziou P, Djulbegovic B, Burls A. Are systematic reviews more cost-effective than randomised trials. Lancet. 2006 Jun;367(9528):2057-2058. Pubmedid: 16798380.
• Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May;98(10):708-714. Pubmedid: 16705125.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 3 November to 24 November, 2005: A summary. Cancer Treat Rev. 2006 May;32(3):239-241. Pubmedid: 16624491.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 25 August to 27 October 2005: A summary. Cancer Treat Rev. 2006 Apr;32(2):149-155. Pubmedid: 16520003.
• Prentice A, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis ofsystemic fungal infection in the treatment of haematological malignancy. Br J Haematol. 2006 Mar;132(5):656-8. Pubmedid: 16445845.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 16 June to 18 August 2005: A summary. Cancer Treat Rev. 2006 Feb;32(1):59-64. Pubmedid: 16434143.
• Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ. 2005 Dec;331(7528):1295. Pubmedid: 16299015. Pmcid: PMC1298846.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 19 May to 9 June 2005: A summary. Cancer Treat Rev. 2005 Dec;31(8):653-656. Pubmedid: 16298072.
• Lyman G, Djulbegovic B. The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev. 2005 Dec;31(8):628-639. Pubmedid: 16225994.
• Rodgers GM 3rd, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia P, Demetri G, Djulbegovic B, Garst J, Gore M, Kraut E, Lin W, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. J Natl Compr Canc Netw. 2005 Nov;3(6):772-789. Pubmedid: 16316613.
• Djulbegovic B, Frohlich A, Bennett C. Acting on imperfect evidence: how much regret are we ready to accept?. J Clin Oncol. 2005 Oct;23(28):6822-6825. Pubmedid: 16145058.
• Djulbegovic B, Kumar A. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005 Aug;23(22):5074-5087. Pubmedid: 16051954.
• Clark O, Lyman G, Castro A, Clark L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005 Jun;23(18):4198-4214. Pubmedid: 15961767.
• Vincent S, Djulbegovic B. Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence. Cancer Treat Rev. 2005 Jun;31(4):319-322. Pubmedid: 16006047.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 1st September to 14th October 2004: a summary. Cancer Treat Rev. 2005 Apr;31(2):155-157. Pubmedid: 15847985.
• Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments?. JAMA. 2005 Feb;293(8):970-978. Pubmedid: 15728168. Pmcid: PMC1779758.
• Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. Cancer Treat Rev. 2005 Feb;31(1):63-67. Pubmedid: 15707707.
• Djulbegovic B. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol. 2005;18(3):455-466. Pubmedid: 15792920.
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. Pubmedid: 15840177. Pmcid: PMC1097734.
• Hozo I, Djulbegovic B, Clark O, Lyman GH. Use of re-randomized data in meta-analysis. BMC Med Res Methodol. 2005;5:17. Pubmedid: 15882470. Pmcid: PMC1145185.
• Djulbegovic B. Lifting the fog of uncertainty from the practice of medicine. BMJ. 2004 Dec;329(7480):1419-1420. Pubmedid: 15604164. Pmcid: PMC535956.
• Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May;103(9):3271-3277. Pubmedid: 14726402.
• Djulbegovic B. Well informed uncertainties about the effects of treatment: paradox exists in dealing with uncertainty. BMJ. 2004 Apr;328(7446):1018. Pubmedid: 15105342. Pmcid: PMC404547.
• Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ. 2004 Jan;328(7430):22-24. Pubmedid: 14703540. Pmcid: PMC313900.
• Djulbegovic B. Where is the evidence. Eur J Cancer. 2004;40(18):2637-2637. Pubmedid: 15648121.
• Djulbegovic B, Vincent S. High-quality evidence in oncology from 20th April to 11th May 2004: a summary. Cancer Treat Rev. 2004;30(7):665-667. Pubmedid: 15531400.
• Djulbegovic B, Vincent S. High-quality evidence in oncology from 18th May to 15th June 2004: a summary. Cancer Treat Rev. 2004;30(8):721-723. Pubmedid: 15541583.
• Durie B, Kyle R, Belch A, Bensinger W, Blade J, Boccadoro M, Child J, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau J, Hungria V, JoshuaD, Ludwig H, Mehta J, Morales A, Morgan G, Nouel A, Oken M, Powles R, RoodmanD, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van NessB. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2004;4:379-398. Pubmedid: 14671610.
• Kumar A, Loughran T, Alsina M, Durie B, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003 May;4(5):293-304. Pubmedid: 12732167.
• Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May;326(7400):1167-1170. Pubmedid: 12775614. Pmcid: PMC156458.
• Mann H, Djulbegovic B. Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol. 2003 Apr;3:7. Pubmedid: 12709266. Pmcid: PMC165581.
• Mann H, Djulbegovic B. Clinical equipoise and the therapeutic misconception. Hastings Cent Rep. 2003;33(5):4-5. Pubmedid: 14696270.
• Clark O, Lyman G, Castro A, Clark L, Djulbegovic. Colony stimulating factors for chemotherapy induced febrile neutropenia: review. Cochrane Database Syst Rev. 2003;(3):3039-3039. Pubmedid: 12917942.
• He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev. 2003;4023-4023. Pubmedid: 12535504.
• Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, ZiskeC, Schmidt-Wolf I. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica. 2003;88(11):1304-1315. Pubmedid: 14607760.
• Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer Control. 2003;10(1):17-41. Pubmedid: 12598853.
• Singh D, Djulbegovic B. Evidence-based Oncology section--policies and scope. Cancer Treat Rev. 2003;29(2):121-122. Pubmedid: 12670454.
• Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res. 2003;10(4):301-315. Pubmedid: 14989285.
• Mann H, Djulbegovic B. Off-study availability of investigational treatments. Lancet. 2003;361(9365):1302-1302. Pubmedid: 12699986.
• Bepler G, Goodridge Carney D, Djulbegovic B, Clark R, Tockman M. A systematic review and lessions learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer Control. 2003;10(4):306-314. Pubmedid: 12915809.
• Djulbegovic B, Singh D. Evidence-based oncology section - aims and scope. Cancer Treat Rev. 2003;29(1):51-53. Pubmedid: 12633580.
• Mann H, Djulbegovic B, Gold P. Failure of equipoise to resolve the ethical tension in a randomized clinical trial. J Law Med Ethics. 2003;31(1):5-6. Pubmedid: 12762098.
• Djulbegovic B, Coleman R, Stahel R, Singh D, Lyman G. Evidence-based oncology in cancer treatment reviews. Cancer Treat Rev. 2003;29(1):45-50. Pubmedid: 12633579.
• Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf I. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21(24):4615-4626. Pubmedid: 14673051.
• Djulbegovic B. Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ. 2002 Dec;325(7377):1420. Pubmedid: 12480865.
• Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct;100(7):2303-2320. Pubmedid: 12239138.
• Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer. 2002 Sep;2:23. Pubmedid: 12270068. Pmcid: PMC130027.
• Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002 Apr;112(5):406-411. Pubmedid: 11904116.
• Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncol. 2002 Mar;3(3):145-153. Pubmedid: 11902500.
• Cruse H, Winiarek M, Marshburn J, Clark O, Djulbegovic B. Quality and methods of developing practice guidelines. BMC Health Serv Res. 2002;2:1. Pubmedid: 11825346. Pmcid: PMC65517.
• Djulbegovic B, Hozo I. At what degree of belief in a research hypothesis is a trial in humans is justified?. J Eval Clin Pract. 2002;8(2):269-276. Pubmedid: 12180373.
• Wheatley K, Djulbegovic B, Glasmacher A. Priority-setting decisions for new cancer drugs. Lancet. 2002;359(6316):1525-1525. Pubmedid: 11988282.
• Gordon M, Lichtin A, Woolf S, Rizzo D, Seidenfeld J, Bennett B, Cella D, Djulbegovic B, Goode M, Jakubowski A, Lee S, Miller C, Rarick M, Regan D. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20(19):4083-4107. Pubmedid: 12351606.
• Kumar A, Djulbegovic B. Why evidence based oncology management. J Oncol Manag. 2002;11(6):13-16. Pubmedid: 12502287.
• Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Erythropoietin improves quality of life--a response. Lancet Oncol. 2002;3(9):527-527. Pubmedid: 12217788.
• Lilford R, Djulbegovic B. Declaration of Helsinki should be strengthened. Equipoise is essential principle of human experimentation. Bmj. 2001;322(7281):299-300. Pubmedid: 11157551.
• Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence clinical trials. Jama. 2001;285(9):1206-1208. Pubmedid: 11231752.
• Djulbegovic B. Placebo-controlled trials. Ann Intern Med. 2001;135(1):62-63. Pubmedid: 11434740.
• Djulbegovic B, Adams J, Lyman G, Lacevic M, Hozo I, Greenwich M, BennettCL. Evaluation and appraisal of randomized controlled trials in myeloma. Ann Oncol. 2001;12(11):1611-1617. Pubmedid: 11822763.
• Lilford R, Djulbegovic B. Uncertainty about clinical equipoise. Equipose and uncertainty principle are not mutually exclusive. Bmj. 2001;795(7289):795-795. Pubmedid: 11322146.
• Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Curr Oncol Rep. 2001;3(5):389-395. Pubmedid: 11489238.
• Djulbegovic B, Clark M. Ethical Issues in the reporting of clinical trials. Jama. 2001;286(13):1577-1578. Pubmedid: 11585477.
• Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. Cochranedatabase Syst Rev. 2001;(4):3188-3188. Pubmedid: 11687178.
• Djulbegovic B, Cohen Y. The natural history of refractory idiopathic thrombocytopenic pupura. Blood. 2001;98(7):2282-2283. Pubmedid: 11592263.
• Djulbegovic B. Acquired anaemias and polycythaemia. Lancet. 2000;356:596-596. Pubmedid: 10950261.
• Djulbegovic B, Hozo I, Lyman G. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. Medgenmed. 2000;2(1):E6-E6. Pubmedid: 11104452.
• Knox K, Adams J, Djulbegovic B, Stinson T, Bennett-Tate C. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol. 2000;11(12):1591-1595. Pubmedid: 11205468.
• Cohen Y, Djulbegovic B, Shamai O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630-1638. Pubmedid: 10847256.
• Djulbegovic B, Hozo I, Lyman G. Talking about treatment. Ann Intern Med. 2000;132(1):94-94. Pubmedid: 10627263.
• Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett-Tate C, Adams J, Kuderer N, Lyman G. The uncertainty principle and industry-sponsored research. Lancet. 2000;356(9230):635-638. Pubmedid: 10968436.
• Djulbegovic B, Morris L, Lyman G. Evidentiary challenges to evidence-based medicine. J Eval Clin Pract. 2000;6(2):99-109. Pubmedid: 10970004.
• Djulbegovic B, Hozo I, Schwartz A, McMasters KM. Acceptable regret in medical decision making. Med Hypotheses. 1999 Sep;53(3):253-259. Pubmedid: 10580533.
• Hozo I, Djulbegovic B. Using internet to Calculate Clinical Action Tresholds. Comput Biomed Res. 1999 Apr;32(2):168-185. Pubmedid: 10337498.
• Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s. Pubmedid: noPMID.
• Djulbegovic B, Hozo I. Computer program for the diagnosis and treatment of polycythemia rubra vera. Md Computing. 1999;16:83-89. Pubmedid: 10202430.
• Djulbegovic B, Hendler F, Pavletic S. Reasoning by identifying goals of treatment. Cancer Control. 1999;6:3 77-384. Pubmedid: 10758570.
• Djulbegovic B, Loughran, Jr. T, Kloecker G, Efthimiadis E, Hadley T, Englert J, Hoskins M, Goldsmith G. A status of the quality of medical evidence in hematology/oncology. Am J Med. 1999;106:198-205. Pubmedid: 10230750.
• Djulbegovic B, Hozo I, Fields K, Sullivan D. High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit risk analysis. Cancer Control. 1998;5:394-405. Pubmedid: 10761089.
• Djulbegovic B, Hadley T. The need and feasibility of evidence-based guidelines in oncology. Oncology. 1998;12:310-314. Pubmedid: 10028514.
• Hozo I, Djulbegovic B. Calculating confidence intervals for threshold and posttest probabilities. Md Computing. 1998;15:110-115. Pubmedid: 9540324.
• Djulbegovic B, Goldsmith G, Vaughn D, Birkimer J, Marasa M, Joseph G, Huang A, Hadley T. Comparison of the quality of life between HIV positive hemophilia patients and HIV negative hemophilia patients. Haemophilia. 1996;2:166-172.
• Djulbegovic B, Desoky A. Equation and nomogram for calculation of testing and treatment thresholds. Med Decis Making. 1996;16:198-199. Pubmedid: 8778540.
• Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol. 1996;51:168-170. Pubmedid: 8579061.
• Mangino P, Taft B, Djulbegovic B. Treatment protocol in oncology. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;453-532.
• Cervera A, Djulbegovic B. Acute myelogenous leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;29-36.
• Djulbegovic B. T-cell lymphoma. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;91-102.
• Djulbegovic B. Chronic myelogenous leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;37-44.
• Beganovic B, Djulbegovic B. Plasma cell disorders. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;103-114.
• Djulbegovic B. Chronic lymphocytic leukemia. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;45-52.
• Djulbegovic B. Principles of reasoning and decision making in oncology. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management.. New York, NY: Churchill Livingstone; 1997;1-14.
• Djulbegovic B. NonHodgkin's lymphoma. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;69-90.
• Yam L, Djulbegovic B. Hodgkin's disease. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology. Evidence-Based Management. New York, NY: Churchill Livingstone; 1997;57-68.
• Djulbegovic B. Reasoning and Decision Making in Hematology. New York, NY: Churchill Livingstone; 1992.
• Clark O, Lyman G, Castro A, Clark L, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. In: The cochrane library. Oxford. Update Software Cochrane; 2003.
• Djulbegovic B. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. J Support Oncol. 210 Mar-Apr;8(2):84-91. Pubmedid: 20464888.